article = {NNB-2021-3-102}
title = {Evaluation of BRAF Gene Status in Gliomas}
journal = {Neurology and Neurobiology}
year = {2021}
issn = {2613-7828}
doi = {http://dx.doi.org/10.31487/j.NNB.2021.03.02}
url = {https://www.sciencerepository.org/evaluation-of-braf-gene-status-in-gliomas_NNB-2021-3-102 
author = {Awadhesh Kumar Jaiswal,Sarita Agrawal,Sushila Jaiswal,Kuntal Kanti Das,Sanjay Behari,Swasti Tewari,Madam Mohan Godbole,Prabhakar  Misra,}
keywords = {BRAF, glioma, pilocytic astrocytoma, brain tumor, MAPK Pathway}
abstract ={Background: Development of different molecular markers has given a new insight in the glioma 
management. KIAA1549-BRAF gene fusion has a diagnostic and prognostic significance. 
Aim: The aim of this study was to determine the KIAA1549-BRAF gene fusion in glioma and their 
correlation with various clinical parameters.
Material and Methods: Forty cases of glioma were studied for KIAA1549-BRAF gene fusion by reverse 
transcription-PCR (RT-PCR).
Results: Overall, KIAA1549-BRAF gene fusion was found in 22% (9/40) cases of glioma. Children had 
higher KIAA1549-BRAF fusion (72%; 8/11) as compared to adults (10%; 3/29) and this difference was 
statistically significant. Cerebellar location of tumor was significantly associated with KIAA1549-BRAF
fusion. KIAA1549-BRAF fusion was highest in pilocytic astrocytoma (89%), and this difference was 
statistically significant. Statistically significant difference was noted between KIAA1549-BRAF fusion 
expression and WHO grade I glioma. 
Conclusion: Overall, KIAA1549-BRAF gene fusion was found in 22% (9/40) cases of glioma. Childhood 
age, pilocytic astrocytoma histology, cerebellar location and WHO grade I tumor were significantly 
associated with KIAA1549-BRAF gene fusion.}